FIGURE 4.

Mean investigator‐confirmed attack rate by months in the intent‐to‐treat population from the APeX‐2 trial for berotralstat. SEM, standard error of the mean. Reprinted from J Allergy Clin Immunol, 148(1), Zuraw B, Lumry WR, Johnston DT, et al., Oral once‐daily berotralstat for the prevention of hereditary angioedema attacks: a randomized, double‐blind, placebo‐controlled phase 3 trial, 164–172, Copyright 2021, with permission from Elsevier. 37